Home
>
National Drug Code (NDC)
>
JAKAFI
JAKAFI - 50881-020-60 - (ruxolitinib)
Drug Information of JAKAFI
| Product NDC: | 50881-020 |
| Proprietary Name: | JAKAFI |
| Non Proprietary Name: | ruxolitinib |
| Active Ingredient(s): | 20 mg/1 & nbsp; ruxolitinib |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of JAKAFI
| Product NDC: | 50881-020 |
| Labeler Name: | Incyte Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA202192 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20111116 |
Package Information of JAKAFI
| Package NDC: | 50881-020-60 |
| Package Description: | 60 TABLET in 1 BOTTLE, PLASTIC (50881-020-60) |
NDC Information of JAKAFI
| NDC Code | 50881-020-60 |
| Proprietary Name | JAKAFI |
| Package Description | 60 TABLET in 1 BOTTLE, PLASTIC (50881-020-60) |
| Product NDC | 50881-020 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | ruxolitinib |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20111116 |
| Marketing Category Name | NDA |
| Labeler Name | Incyte Corporation |
| Substance Name | RUXOLITINIB |
| Strength Number | 20 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
